Posted by Michael Wonder on 11 Oct 2021
Takeda's ovarian cancer drug Zejula gets expanded insurance benefit
1 October 2021 - Takeda Korea said its ovarian cancer treatment Zejula would receive expanded health insurance coverage as maintenance therapy for breast cancer (BRCA) susceptibility gene-mutated ovarian cancer patients who responded to first-line platinum-based therapy from Friday.
Under the latest revision, the government will reimburse the treatment as maintenance therapy for patients with advanced BRCA mutated epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer who have responded (complete response or partial response) to first-line platinum-based therapy.
